Oxaliplatine Teva (Oxaliplatin)

Oxaliplatin is a platinum‑based chemotherapeutic agent used in the treatment of cancers that involve the gastrointestinal tract and related pathways.

• Colorectal cancer: improves survival when combined with fluorouracil and leucovorin.
• Gastric cancer: used as part of combination regimens for advanced disease.
• Pancreatic cancer: contributes to tumour response in multi‑drug protocols.
• Ovarian cancer: employed in certain platinum‑sensitive relapse settings.
• Esophageal cancer: added to standard chemotherapy backbones for better disease control.

• Oxaliplatin forms reactive platinum complexes that bind to DNA, creating intra‑ and interstrand cross‑links that inhibit DNA replication and transcription. This DNA damage triggers cell‑cycle arrest and apoptosis, preferentially affecting rapidly dividing cancer cells while sparing most normal tissues.

Oxaliplatin may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting: mild to moderate gastrointestinal upset.
• Peripheral neuropathy: tingling or numbness, often dose‑related.
• Diarrhoea: loose stools that may require supportive care.
• Fatigue: generalized tiredness during treatment cycles.
• Myelosuppression: reduced blood cell counts, increasing infection risk.

Serious or Rare Side Effects

• Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate medical attention.
• Acute pulmonary toxicity: breathing difficulties and reduced oxygen exchange.
• Severe neutropenia: markedly low neutrophil counts leading to infection.
• Thrombocytopenia: low platelet counts causing bleeding tendencies.
• Cardiotoxicity: rare heart rhythm disturbances or myocardial injury.

When using Oxaliplatin, clinicians should assess patient suitability and monitor for adverse events throughout therapy.

• Renal function: evaluate baseline creatinine and adjust if impairment is present.
• Neuropathy risk: monitor for sensory changes and modify dosing if symptoms progress.
• Hematologic monitoring: perform regular CBCs to detect myelosuppression.
• Hypersensitivity: be prepared to manage infusion‑related reactions.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Store at ambient temperature: keep in original container, protect from light and moisture.

Oxaliplatin may interact with several concomitant medications, requiring careful review.

Major Interactions (Avoid)

• Nephrotoxic agents: concurrent use with high‑dose cisplatin or aminoglycosides may worsen renal injury.
• Anticoagulants: increased bleeding risk when combined with warfarin or direct oral anticoagulants.

Moderate Interactions (Monitor Closely)

• Antiemetics: certain serotonin‑receptor antagonists can alter oxaliplatin clearance.
• CYP450 inducers: drugs like rifampicin may reduce plasma exposure.
• Radiotherapy: combined modality may heighten neurotoxicity.
• Herbal supplements: St St  ??